Table 1 Clinicopathological characteristics of the studied population
Case | Control | P | |
|---|---|---|---|
n (%) | n (%) | ||
Cancer family history | |||
Yes | 24 (63.16) | 7 (40.0) | 0.0410* |
No | 14 (36.84) | 13 (60.0) | |
n (%), age+ | n (%), age+ | ||
|---|---|---|---|
Menopause | |||
Premenopause | 12 (31.6) 41.33 ± 5.97 | 15 (75.0) 34.80 ± 12.42 | 0.0016* |
Postmenopause | 26 (68.4) 57.58 ± 12.56 | 5 (25.0) 49.60 ± 20.21 | |
Cancer stage grouping | |||
I | 1 (2.6) | NA | |
II | 18 (47.4) | NA | |
III | 15 (39.5) | NA | |
IV | 4 (10.5) | NA | |
Phenotype | |||
Luminal/HER2+ | 11 (28.9) | NA | |
HER2+ | 11 (28.9) | NA | |
Luminal A | 4 (10.5) | NA | |
Mixed phenotypea | 7 (18.4) | NA | |
Triple-negative | 5 (13.2) | NA | |
Case, n (%) | Control, n (%) | P | |
|---|---|---|---|
Immunohistochemical profileb | |||
Estrogen receptor (ER) | Positive | Negative | |
Triple-negative | 19 (50.0) | 19 (50.0) | NA |
Progesterone receptor | 18 (47.4) | 20 (52.6) | NA |
HER2+ | 26 (68.4) | 12 (31.6) | NA |